Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMCKH3P)

Drug Name

Anandamide Drug Info

Synonyms

Anandamide; Arachidonylethanolamide; Arachidonoyl ethanolamide; N-Arachidonoylethanolamine; Anandamide (20.4, n-6); N-Arachidonoyl-2-hydroxyethylamide; 94421-68-8; AEA; N-arachidonoyl ethanolamine; N-(2-Hydroxyethyl)anachidonamide; 5,8,11,14-Eicosatetraenoylethanolamide; arachidonoylethanolamide; (5Z,8Z,11Z,14Z)-N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide; Arachidonoyl-EA; UNII-UR5G69TJKH; Arachidonic acid N-(hydroxyethyl)amide; Anandamide(20:4, n-6); Anandamide (20:4, n-6)

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 5281969
ChEBI ID: CHEBI:2700
CAS Number: CAS 94421-68-8
TTD Drug ID: DMCKH3P

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cannabinoid receptor 1 (CB1)	TT6OEDT	CNR1_HUMAN	Agonist	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Cannabinoid receptor 1 (CB1)	DTT	CNR1	2.907	4.667	2.982	3.678

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Discovery agent

ICD Disease Classification

N.A.

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Cannabinoid receptor 1 (CB1)	DTT	CNR1	5.59E-02	-0.22	-0.45
Cannabinoid receptor 1 (CB1)	DTT	CNR1	7.68E-01	-0.06	-0.46

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2364).
2	Opioid receptor and NO/cGMP pathway as a mechanism of peripheral antinociceptive action of the cannabinoid receptor agonist anandamide. Life Sci. 2009 Aug 26;85(9-10):351-6.